Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile

被引:16
作者
deJong, RS
Slijfer, EAM
Uges, DRA
Mulder, NH
deVries, EGE
机构
[1] UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,NL-9700 RB GRONINGEN,NETHERLANDS
[2] UNIV GRONINGEN HOSP,DEPT PHARM & TOXICOL,NL-9700 RB GRONINGEN,NETHERLANDS
关键词
alkaline phosphatase; bile; etoposide phosphate; gastric juice; pharmacology; prodrug;
D O I
10.1038/bjc.1997.581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Etoposide phosphate is a water-soluble prodrug of etoposide. It was expected that this prodrug could be used to overcome the solubility limitations and erratic bioavailability of oral etoposide. To investigate the possibility of prodrug conversion to etoposide within the gastrointestinal lumen, etoposide phosphate was dissolved in water and incubated with human gastric juice or human bile in vitro. Samples were collected during 150 min and analysed for etoposide concentration with high-performance liquid chromatography. Conversion of prodrug to etoposide during incubation with gastric juice was negligible. There was significant conversion during incubation with bile at pH 7-8. The percentage of prodrug converted to etoposide at pH 8 after 60 min was 78 +/- 18% (mean +/- S.D.) for a 0.1 mg ml(-1) prodrug solution and 36 +/- 26% for 0.5 mg ml(-1). At pH 7, after 60 min 22% of prodrug was converted to etoposide when incubated at 0.1 mg ml(-1) and 10% at 0.5 mg ml(-1). No conversion was found after inactivation of alkaline phosphate (AP) by overnight heating of bile at 65 degrees C or by the addition of disodium edetate to the bile. In conclusion, because of AP in bile, variable conversion of etoposide phosphate to etoposide can be expected within the intestinal lumen after oral administration. This could have important pharmacokinetic consequences.
引用
收藏
页码:1480 / 1483
页数:4
相关论文
共 15 条
  • [1] Davenport H.W., 1977, Physiology of the Digestive Tract
  • [2] Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide
    deJong, RS
    Mulder, NH
    Uges, DRA
    Kaul, S
    Winograd, B
    Sleijfer, DT
    Groen, HJM
    Willemse, PHB
    vanderGraaf, WTA
    deVries, EGE
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (11) : 1660 - 1666
  • [3] DeJong RS, 1995, ANTICANCER RES, V15, P2319
  • [4] FALLINGBORG J, 1989, ALIMENT PHARM THERAP, V3, P605
  • [5] BIOAVAILABILITY OF LOW-DOSE ORAL ETOPOSIDE
    HANDE, KR
    KROZELY, MG
    GRECO, FA
    HAINSWORTH, JD
    JOHNSON, DH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 374 - 377
  • [6] VARIABLE BIOAVAILABILITY FOLLOWING REPEATED ORAL DOSES OF ETOPOSIDE
    HARVEY, VJ
    SLEVIN, ML
    JOEL, SP
    SMYTHE, MM
    JOHNSTON, A
    WRIGLEY, PFM
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (11): : 1315 - 1319
  • [7] A SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR DETERMINATION OF THE ANTI-NEOPLASTIC AGENTS VP-16-213 AND VM-26 IN BIOLOGICAL-FLUIDS
    HOLTHUIS, JJM
    VANOORT, WJ
    PINEDO, HM
    [J]. ANALYTICA CHIMICA ACTA, 1981, 130 (01) : 23 - 30
  • [8] JOEL SP, 1995, CANCER CHEMOTH PHARM, V37, P117
  • [9] MOSS DW, 1986, TXB CLIN CHEM, P704
  • [10] SYNTHESIS OF ETOPOSIDE PHOSPHATE, BMY-40481 - A WATER-SOLUBLE CLINICALLY ACTIVE PRODRUG OF ETOPOSIDE
    SAULNIER, MG
    LANGLEY, DR
    KADOW, JF
    SENTER, PD
    KNIPE, JO
    TUN, MM
    VYAS, DM
    DOYLE, TW
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (21) : 2567 - 2572